Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab for anti-Hu associated paraneoplastic neurological syndromes
2014-000675-13Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of natalizumab in paraneoplastic neurological syndrome (PNS), sponsored by Erasmus MC. Primary endpoint: Functional improvement on modified Rankin Scale. Started Oct 2015; status: completed.
02
Drugs
natalizumab
03
Conditions
paraneoplastic neurological syndrome (PNS)
Beyond the preview
Go deeper on 2014-000675-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000675-13.